Biobanking Market by Specimen Type (Blood Products, Solid Tissue, Nucleic Acid, and Cell Lines), Type of Biobank (Population-based Biobanks and Disease-oriented Biobanks), Ownership (National/Regional Agencies, Nonprofit Organization, University, and Private Organization), and Application (Therapeutic and Research): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4162556
- 245 Pages
- October 2020
- Pharmaceuticals
Biobank is a biorepository meant to collect and preserve biological materials that are used for diagnosis, biodiversity studies, and research. In addition, it is used to support the research of most common types of genetic disorders to develop personalized medicines and to maintain and update database of diseases related to age.
Rise in funding by private & government organizations for biobanking and increase in application areas of bio banked samples are the major factors that drive the growth of the global biobanking market. Moreover, upsurge in incidence of diseases such as cancer significantly contributes toward the market growth, owing to the fact that biobanked specimens are used in the treatment of several chronic diseases. However, ethical issues related to biobanking and lack of awareness about it are expected to impede the market growth. On the contrary, advancements in stem cell research and unmet medical needs in emerging nations are anticipated to provide lucrative opportunity for the market expansion.
Rise in genomic research activities acts as a key driving force of the global market. Furthermore, government is taking multiple initiatives to support regenerative medicine research, which is expected to boost the market growth. Moreover, increase in demand for cost-effective drug delivery & development accelerates the market growth. Furthermore, usage of human biospecimens is increasing in cohort studies. Number of registered clinical studies with the National Institutes of Health (NIH) increased from 181,305 in 2014 to 262,445 in 2017. A substantial number of large ongoing cohort studies related to precision medicine have fomented the establishment of population-based banks.
The global biobanking market is segmented into specimen type, type of biobank, ownership, application, and region. Depending on specimen type, the market is categorized into blood products, solid tissue, cell lines, nucleic acid, and others. On the basis of ownership, it is divided into national/regional agencies, nonprofit organization, universities, and private organization. The applications covered in the study include therapeutic and research. By type of biobank, the market is bifurcated into population-based biobank and disease-oriented biobank. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global market for biobanks are BioIVT & Elevating Science, Geneticist Inc, Firalis S.A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, CTI Biotech, and Boca Biolistics.
KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global biobanking market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
• By Specimen Type
o Blood products
o Solid tissue
o Cell lines
o Nucleic acid
o Others
• By Application
o Therapeutic
o Research
• By Type of Biobank
o Population-based biobanks
o Disease-oriented biobanks
• By Ownership
o National/regional agencies
o Nonprofit organization
o Universities
o Private Organization
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
The key players profiled in this report are as follows:
• BioIVT & Elevating Science
• Geneticist Inc.
• Firalis S.A.
• AMS biotechnology Ltd. (AMSBIO LLC)
• US Biolab Corporation, Inc.
• ProteoGenex, Inc.
• Cureline, Inc.
• Bay Biosciences LLC
• CTI Biotech
• Boca Biolistics
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.1.Research methodology
1.1.1.Secondary research
1.1.2.Primary research
1.1.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top player positioning
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers, restraints, and opportunity
3.4.2.Drivers
3.4.2.1.Rise in funds for biobanks
3.4.2.2.Increase in R&D activities for application of biobank specimens
3.4.2.3.Surge in prevalence of fatal chronic diseases
3.4.3.Restraints
3.4.3.1.Legal and ethical issues of biobanking
3.4.3.2.Lack of awareness toward biobanking
3.4.4.Opportunity
3.4.4.1.High growth potential in developing countries
3.5.Impact of COVID-19 on biobanking market
3.5.1.Overview
3.5.2.Impact analysis
3.5.3.List of 10 largest biobanks across the globe
CHAPTER 4:BIOBANKING MARKET, BY SPECIMEN TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Blood products
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Solid tissues
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Cell lines
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Nucleic acid
4.5.1.Key market trends and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Others
4.6.1.Key market trends and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
CHAPTER 5:BIOBANKING MARKET, BY TYPE OF BIOBANK
5.1.Overview
5.1.1.Market size and forecast
5.2.Population-based biobanks
5.2.1.Key market trends and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Disease-oriented biobanks
5.3.1.Key market trends and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
CHAPTER 6:BIOBANKING MARKET, BY OWNERSHIP
6.1.Overview
6.1.1.Market size and forecast
6.2.National/regional agencies
6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Nonprofit organization
6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.Universities
6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
6.5.Private organization
6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis, by country
CHAPTER 7:BIOBANKING MARKET, BY APPLICATION
7.1.Overview
7.1.1.Market size and forecast
7.2.Therapeutic
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market analysis, by country
7.3.Research
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market analysis, by country
CHAPTER 8:BIOBANKING MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America market size and forecast, by country
8.2.2.1.U.S. biobanking market size and forecast, by specimen type
8.2.2.2.U.S. biobanking market size and forecast, by type of biobank
8.2.2.3.U.S. biobanking market size and forecast, by ownership
8.2.2.4.U.S. biobanking market size and forecast, by application
8.2.2.5.Canada biobanking market size and forecast, by specimen type
8.2.2.6.Canada biobanking market size and forecast, by type of biobank
8.2.2.7.Canada biobanking market size and forecast, by ownership
8.2.2.8.Canada biobanking market size and forecast, by application
8.2.2.9.Mexico biobanking market size and forecast, by specimen type
8.2.2.10.Mexico biobanking market size and forecast, by type of biobank
8.2.2.11.Mexico biobanking market size and forecast, by ownership
8.2.2.12.Mexico biobanking market size and forecast, by application
8.2.3.North America market size and forecast, by specimen type
8.2.4.North America market size and forecast, by type of biobank
8.2.5.North America biobanking market size and forecast, by ownership
8.2.6.North America biobanking market size and forecast, by application
8.3.Europe
8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Europe market size and forecast, by country
8.3.2.1.Germany biobanking market size and forecast, by specimen type
8.3.2.2.Germany biobanking market size and forecast, by type of biobank
8.3.2.3.Germany biobanking market size and forecast, by ownership
8.3.2.4.Germany biobanking market size and forecast, by application
8.3.2.5.France biobanking market size and forecast, by specimen type
8.3.2.6.France biobanking market size and forecast, by type of biobank
8.3.2.7.France biobanking market size and forecast, by ownership
8.3.2.8.France biobanking market size and forecast, by application
8.3.2.9.UK biobanking market size and forecast, by specimen type
8.3.2.10.UK biobanking market size and forecast, by type of biobank
8.3.2.11.UK biobanking market size and forecast, by ownership
8.3.2.12.UK biobanking market size and forecast, by application
8.3.2.13.Italy biobanking market size and forecast, by specimen type
8.3.2.14.Italy biobanking market size and forecast, by type of biobank
8.3.2.15.Italy biobanking market size and forecast, by ownership
8.3.2.16.Italy biobanking market size and forecast, by application
8.3.2.17.Spain biobanking market size and forecast, by specimen type
8.3.2.18.Spain biobanking market size and forecast, by type of biobank
8.3.2.19.Spain biobanking market size and forecast, by ownership
8.3.2.20.Spain biobanking market size and forecast, by application
8.3.2.21.Rest of Europe biobanking market size and forecast, by specimen type
8.3.2.22.Rest of Europe biobanking market size and forecast, by type of biobank
8.3.2.23.Rest of Europe biobanking market size and forecast, by ownership
8.3.2.24.Rest of Europe biobanking market size and forecast, by application
8.3.3.Europe market size and forecast, by specimen type
8.3.4.Europe market size and forecast, by type of biobank
8.3.5.Europe biobanking market size and forecast, by ownership
8.3.6.Europe biobanking market size and forecast, by application
8.4.Asia-Pacific
8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Asia-Pacific market size and forecast, by country
8.4.2.1.Japan biobanking market size and forecast, by specimen type
8.4.2.2.Japan biobanking market size and forecast, by type of biobank
8.4.2.3.Japan biobanking market size and forecast, by ownership
8.4.2.4.Japan biobanking market size and forecast, by application
8.4.2.5.China biobanking market size and forecast, by specimen type
8.4.2.6.China biobanking market size and forecast, by type of biobank
8.4.2.7.China biobanking market size and forecast, by ownership
8.4.2.8.China biobanking market size and forecast, by application
8.4.2.9.India biobanking market size and forecast, by specimen type
8.4.2.10.India biobanking market size and forecast, by type of biobank
8.4.2.11.India biobanking market size and forecast, by ownership
8.4.2.12.India biobanking market size and forecast, by application
8.4.2.13.Australia biobanking market size and forecast, by specimen type
8.4.2.14.Australia biobanking market size and forecast, by type of biobank
8.4.2.15.Australia biobanking market size and forecast, by ownership
8.4.2.16.Australia biobanking market size and forecast, by application
8.4.2.17.Rest of Asia-Pacific biobanking market size and forecast, by specimen type
8.4.2.18.Rest of Asia-Pacific biobanking market size and forecast, by type of biobank
8.4.2.19.Rest of Asia-Pacific biobanking market size and forecast, by ownership
8.4.2.20.Rest of Asia-Pacific biobanking market size and forecast, by application
8.4.3.Asia-Pacific market size and forecast, by specimen type
8.4.4.Asia-Pacific market size and forecast, by type of biobank
8.4.5.Asia-Pacific biobanking market size and forecast, by ownership
8.4.6.Asia-Pacific biobanking market size and forecast, by application
8.5.LAMEA
8.5.1.Key market trends, growth factors, and opportunities
8.5.2.LAMEA market size and forecast, by country
8.5.2.1.Brazil biobanking market size and forecast, by specimen type
8.5.2.2.Brazil biobanking market size and forecast, by type of biobank
8.5.2.3.Brazil biobanking market size and forecast, by ownership
8.5.2.4.Brazil biobanking market size and forecast, by application
8.5.2.5.South Africa biobanking market size and forecast, by specimen type
8.5.2.6.South Africa biobanking market size and forecast, by type of biobank
8.5.2.7.South Africa biobanking market size and forecast, by ownership
8.5.2.8.South Africa biobanking market size and forecast, by application
8.5.2.9.Saudi Arabia biobanking market size and forecast, by specimen type
8.5.2.10.Saudi Arabia biobanking market size and forecast, by type of biobank
8.5.2.11.Saudi Arabia biobanking market size and forecast, by ownership
8.5.2.12.Saudi Arabia biobanking market size and forecast, by application
8.5.2.13.Rest of LAMEA biobanking market size and forecast, by specimen type
8.5.2.14.Rest of LAMEA biobanking market size and forecast, by type of biobank
8.5.2.15.Rest of LAMEA biobanking market size and forecast, by ownership
8.5.2.16.Rest of LAMEA biobanking market size and forecast, by application
8.5.3.LAMEA market size and forecast, by specimen type
8.5.4.LAMEA market size and forecast, by type of biobank
8.5.5.LAMEA biobanking market size and forecast, by ownership
8.5.6.LAMEA biobanking market size and forecast, by application
CHAPTER 9:COMPANY PROFILES
9.1.AMS BIOTECHNOLOGY LTD. (AMSBIO LLC)
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.2.BAY BIOSCIENCES LLC
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.3.BIOIVT & ELEVATING SCIENCE
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Key strategic moves and developments
9.4.BOCA BIOLISTICS
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.5.CTI BIOTECH
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Product portfolio
9.6.CURELINE, INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.7.FIRALIS S.A.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.8.GENETICIST INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.9.PROTEOGENEX, INC.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.10.US BIOLAB CORPORATION, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
TABLE 01.BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 02.BIOBANKING MARKET REVENUE FOR BLOOD PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.BIOBANKING MARKET REVENUE FOR SOLID TISSUE, BY REGION, 2019–2027 ($MILLION)
TABLE 04.BIOBANKING MARKET REVENUE FOR CELL LINES, BY REGION, 2019–2027 ($MILLION)
TABLE 05.BIOBANKING MARKET REVENUE FOR NUCLEIC ACID SAMPLES, BY REGION, 2019–2027 ($MILLION)
TABLE 06.BIOBANKING MARKET REVENUE FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 08.POPULATION-BASED BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 09.DISEASE-ORIENTED BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 10.BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 11.BIOBANKING MARKET REVENUE FOR NATIONAL/REGIONAL AGENCY, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BIOBANKING MARKET REVENUE FOR NONPROFIT ORGANIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 13.BIOBANKING MARKET REVENUE FOR UNIVERSITY, BY REGION, 2019–2027 ($MILLION)
TABLE 14.BIOBANKING MARKET REVENUE FOR PRIVATE ORGANIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 15.BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.BIOBANKING MARKET REVENUE FOR THERAPEUTIC APPLICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 17.BIOBANKING MARKET REVENUE FOR RESEARCH APPLICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 18.BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.U.S. BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 21.U.S. BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 22.U.S. BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 23.U.S. BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 24.CANADA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 25.CANADA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 26.CANADA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 27.CANADA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 28.MEXICO BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 29.MEXICO BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 30.MEXICO BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 31.MEXICO BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 32.NORTH AMERICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 33.NORTH AMERICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 36.EUROPE BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 37.GERMANY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 38.GERMANY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 39.GERMANY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 40.GERMANY BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 41.FRANCE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 42.FRANCE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 43.FRANCE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 44.FRANCE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 45.UK BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 46.UK BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 47.UK BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 48.UK BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 49.ITALY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 50.ITALY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 51.ITALY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 52.ITALY BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 53.SPAIN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 54.SPAIN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 55.SPAIN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 56.SPAIN BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.REST OF EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 58.REST OF EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 59.REST OF EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 62.EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 63.EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 64.EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 66.JAPAN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 67.JAPAN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 68.JAPAN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 69.JAPAN BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 70.CHINA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 71.CHINA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 72.CHINA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 73.CHINA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 74.INDIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 75.INDIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 76.INDIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 77.INDIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 78.AUSTRALIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 79.AUSTRALIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 80.AUSTRALIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 82.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 83.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 84.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 86.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 87.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 88.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 89.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 90.LAMEA BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 91.BRAZIL BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 92.BRAZIL BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 93.BRAZIL BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 94.BRAZIL BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 95.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 96.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 97.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 98.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 99.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 102.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 103.REST OF LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 104.REST OF LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 105.REST OF LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 106.REST OF LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 107.LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 108.LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 109.LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 110.LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 111.AMSBIO: COMPANY SNAPSHOT
TABLE 112.AMSBIO: PRODUCT CATEGORY
TABLE 113.AMSBIO: PRODUCT PORTFOLIO
TABLE 114.BAY BIOSCIENCES: COMPANY SNAPSHOT
TABLE 115.BAY BIOSCIENCES: PRODUCT CATEGORY
TABLE 116.BAY BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 117.BIOIVT: COMPANY SNAPSHOT
TABLE 118.BIOIVT: OPERATING SEGMENTS
TABLE 119.BIOIVT: PRODUCT PORTFOLIO
TABLE 120.BOCA BIOLISTICS: COMPANY SNAPSHOT
TABLE 121.BOCA BIOLISTICS: OPERATING SEGMENTS
TABLE 122.BOCA BIOLISTICS: PRODUCT PORTFOLIO
TABLE 123.CTI BIOTECH: COMPANY SNAPSHOT
TABLE 124.CTI BIOTECH: SERVICE PORTFOLIO
TABLE 125.CURELINE: COMPANY SNAPSHOT
TABLE 126.FIRALIS: OPERATING SEGMENTS
TABLE 127.CURELINE: SERVICE PORTFOLIO
TABLE 128.FIRALIS: COMPANY SNAPSHOT
TABLE 129.FIRALIS: OPERATING SEGMENTS
TABLE 130.FIRALIS: SERVICE PORTFOLIO
TABLE 131.GENETICIST: COMPANY SNAPSHOT
TABLE 132.HAMILTON COMPANY: SEGMENTS
TABLE 133.GENETICIST: PRODUCT PORTFOLIO
TABLE 134.PROTEOGENEX: COMPANY SNAPSHOT
TABLE 135.PROTEOGENEX: OPERATING SEGMENTS
TABLE 136.PROTEOGENEX: PRODUCT PORTFOLIO
TABLE 137.US BIOLAB: COMPANY SNAPSHOT
TABLE 138.US BIOLAB: OPERATING SEGMENTS
TABLE 139.US BIOLAB: PRODUCT PORTFOLIO
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
